Meisam Naeimi, Associate Professor of Pediatrics and Director of Innovation in Cell and Gene Therapy, shared a post by CARTx Therapeutics on LinkedIn, adding:
“Exciting news for CARTx Therapeutics as our company advances toward its first-in-human clinical trials.
CARTx Therapeutics and CGT Global have begun screening healthy blood donors to source allogeneic, HLA-typed γδT cells for CARTx’s upcoming first-in-human trial. More exciting updates to come.
Thanks Impact Phase Global for accelerating the process and getting us ready for helping people around the world with affordable and accessible off-the-shelf CART cells.”
Quoting CARTx Therapeutics’s post:
“CARTx Therapeutics and CGT Global have begun screening healthy blood donors to source healthy allogeneic HLA-tested #γδT cells for CARTx’s first-in-human trial in the near future. More exciting news to come.”
Other articles about Meisam Naeimi on OncoDaily.